Slate Bio

Slate Bio is an immunotherapy development company that develops therapies utilizing bifunctional IL233 cytokines to restore the body's natural immune response across various diseases, providing users with independently synergistic pathways featuring greater tissue selectivity and improved pharmacodynamics. Slate’s lead compound is a bifunctional IL233 cytokine that enhances Treg and expands tissue-resident Treg.